ARQT – arcutis biotherapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen [Yahoo! Finance]
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis [Yahoo! Finance]
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
Arcutis Biotherapeutics (ARQT) had its price target lowered by Mizuho from $37.00 to $35.00. They now have an "outperform" rating on the stock.
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
Form 4 Arcutis Biotherapeutics, For: Mar 02 Filed by: Leonard Keith R
Form 4 Arcutis Biotherapeutics, For: Mar 02 Filed by: Welgus Howard G.
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Edwards Larry Todd
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Watanabe Todd
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Matsuda Masaru
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.